Ropeginterferon alfa-2b for COVID-19: real-time analysis

Download Image

Post

c19early.org

Ropeginterferon alfa-2b for COVID-19

1 study with 132 patients

Serious outcome risk

Ropeginterferon alfa-2b

Control

Significantly lower risk for ventilation.

COVID-19 Ropeginterferon alfa-2b studies · October 2026

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (1)−3%

Mortality (1)−3%

RCTs (1)−3%

Early (1)−3%

00.511.5+

← Ropeginterferon
alfa-2b
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}

Ropeginterferon Alfa-2b is a long-acting, mono-pegylated recombinant Type I interferon biologic administered via subcutaneous injection.


May 21 2024	Liu et al., Infectious Diseases and Therapy, doi:10.1007/s40121-024-00992-5	A Phase 3, Randomized, Controlled Trial Evaluating the Efficacy and Safety of Ropeginterferon Alfa-2b in Patients with Moderate COVID-19
May 21 2024	90% lower ventilation (p=0.04), 3% higher need for oxygen therapy (p=1), and 4% improved recovery (p=1). RCT 132 hospitalized moderate COVID-19 patients in Taiwan showing higher rates of viral clearance or discharge by day 11 with ropeginterferon alfa-2b. The ropeginterferon alfa-2b group also showed higher rates of improvement in lung infil..